Economic Daily-China Economic Net Beijing, March 9 (Reporter Zhu Guowang Yang Qiqi) "During the '14th Five-Year Plan', the government's focus will shift from'examination and approval' to'supervision', and the continuous improvement of policies and systems will stimulate the growth of pharmaceutical companies The research and development of large-scale innovative drugs will drive the overall innovation and upgrading of the pharmaceutical industry and promote the high-quality development of my country's pharmaceutical industry.” A few days ago, Fang Tonghua, deputy to the National People’s Congress and chairman of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., was interviewed by a reporter from Economic Daily-China Economic Net So said.

Since the official establishment of the National Medical Security Administration in 2018, the pharmaceutical industry has implemented a new round of systematic regulatory reforms and policy reforms from top to bottom, and major adjustments have taken place from the regulatory agencies to the upstream and downstream of the industrial chain. Regulatory systems and policies provide various institutional innovations for the R&D side of pharmaceutical companies. Join ICH (International Coordinating Council for Technical Requirements for Human Drugs) to promote the process of internationalization; R&D projects with clinical value pass the priority review green channel, minus The unnecessary queuing time is eliminated; the time period for the research and development of innovative drugs has been shortened in the listing approval process; the waiting time for new drugs to enter the medical insurance catalog after the listing is also significantly shortened...A series of system reform dividends are gradually released, effectively stimulating the innovation of pharmaceutical companies vitality.

Fang Tonghua said that the "14th Five-Year Plan" will bring important opportunities to the pharmaceutical industry. my country is moving from a "big pharmaceutical country" to a "powerful pharmaceutical country." The regulatory system and related policies of my country's pharmaceutical industry are gradually optimized, which can effectively promote the high-quality development of my country's pharmaceutical industry. Innovative R&D will also form an open R&D model with capital boost, patent authorization, and participation of third-party R&D institutions. Intelligent manufacturing based on the modern pharmaceutical industry system will also be basically formed, thereby further accelerating the transformation and upgrading of the pharmaceutical industry.

As a representative of Chinese medicine companies, what are your thoughts on how to vigorously develop the Chinese medicine industry during the "14th Five-Year Plan" period? Fang Tonghua said that first, through continuous improvement of policies and regulations, more pharmaceutical companies must increase their R&D investment in the field of innovative medicines. Secondly, it is necessary to benchmark against the international advanced level, through the improvement of process and technology, to promote the continuous improvement of drug quality standards, so as to ensure the quality of high-quality drugs; thirdly, to increase the scientific popularization and promotion of drug knowledge to the public, so that the public will "passively accept "Transition to "active participation" to increase the demand for Chinese medicine products, thereby promoting the high-quality development of the Chinese medicine industry; the most important thing is that pharmaceutical companies, capital and society pay attention to drug innovation and research, and only the R&D and innovation capabilities are enhanced. Only by continuously lowering the price of medicines can the safety and reliability of medicines used by the people be guaranteed.

It is understood that the next step of Zhenbaodao Pharmaceutical is to build an ecological closed loop of the Chinese medicinal material trading system with the "Bozhou Chinese Medicinal Material Commodity Trading Center" as the core, to ensure the authenticity and reliability of Chinese medicinal materials from the source, and to realize the information of the Chinese medicinal materials trading system. Globalization, digitization and internationalization. On the other hand, we will increase the R&D and innovation of Chinese medicine products, focus on the protection of famous and old Chinese medicine and the discovery of classic prescriptions, and will also carry out a comprehensive strategic layout in the research, production and marketing of hospital preparations and formula granules.